Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5.51M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
50
-
Shares change
-
-221K
-
Total reported value, excl. options
-
$2.00
-
Value change
-
-$117K
-
Number of buys
-
1
-
Number of sells
-
-13
-
Price
-
$0.04
Significant Holders of Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share (VINC) as of Q2 2025
14 filings reported holding VINC - Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share as of Q2 2025.
Vincerx Pharma, Inc. - Common Stock, $0.0001 par value per share (VINC) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50 shares
of 5.51M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include Bank & Trust Co (50 shares), SAGE RHINO CAPITAL LLC (0 shares), GEODE CAPITAL MANAGEMENT, LLC (0 shares), SBI Securities Co., Ltd. (0 shares), VANGUARD GROUP INC (0 shares), BlackRock, Inc. (0 shares), BANK OF AMERICA CORP /DE/ (0 shares), GOLDMAN SACHS GROUP INC (0 shares), MORGAN STANLEY (0 shares), and MILLENNIUM MANAGEMENT LLC (0 shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.